BRYN MAWR TRUST Co Has $12.19 Million Holdings in Amgen, Inc. (AMGN)

BRYN MAWR TRUST Co raised its holdings in Amgen, Inc. (NASDAQ:AMGN) by 2.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 66,029 shares of the medical research company’s stock after buying an additional 1,307 shares during the quarter. BRYN MAWR TRUST Co’s holdings in Amgen were worth $12,188,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. HC Financial Advisors Inc. bought a new stake in Amgen during the 4th quarter valued at $1,924,000. Boston Partners boosted its position in Amgen by 7.5% during the 1st quarter. Boston Partners now owns 9,952 shares of the medical research company’s stock valued at $1,697,000 after acquiring an additional 698 shares in the last quarter. Ffcm LLC bought a new stake in Amgen during the 1st quarter valued at $614,000. LSV Asset Management boosted its position in Amgen by 5.6% during the 1st quarter. LSV Asset Management now owns 4,028,784 shares of the medical research company’s stock valued at $686,827,000 after acquiring an additional 214,013 shares in the last quarter. Finally, Sandy Spring Bank boosted its position in Amgen by 8.5% during the 1st quarter. Sandy Spring Bank now owns 15,177 shares of the medical research company’s stock valued at $2,587,000 after acquiring an additional 1,195 shares in the last quarter. 77.20% of the stock is currently owned by institutional investors and hedge funds.

AMGN has been the topic of several recent research reports. Mizuho reaffirmed a “buy” rating and set a $200.00 target price on shares of Amgen in a research report on Friday, July 27th. Oppenheimer reiterated a “buy” rating and set a $224.00 price objective on shares of Amgen in a report on Tuesday, August 28th. Jefferies Financial Group increased their price objective on Amgen from $200.00 to $220.00 and gave the company a “buy” rating in a report on Friday, July 27th. Robert W. Baird increased their price objective on Amgen from $165.00 to $179.00 and gave the company a “neutral” rating in a report on Monday, July 30th. Finally, Royal Bank of Canada reiterated a “neutral” rating and set a $193.00 price objective on shares of Amgen in a report on Monday. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eleven have assigned a buy rating to the company. Amgen presently has an average rating of “Hold” and a consensus target price of $202.76.

Shares of AMGN stock opened at $202.93 on Friday. The firm has a market capitalization of $129.11 billion, a P/E ratio of 16.13, a PEG ratio of 1.94 and a beta of 1.39. The company has a quick ratio of 3.12, a current ratio of 3.39 and a debt-to-equity ratio of 2.03. Amgen, Inc. has a 1 year low of $163.31 and a 1 year high of $203.69.

Amgen (NASDAQ:AMGN) last issued its earnings results on Thursday, July 26th. The medical research company reported $3.83 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.52 by $0.31. The company had revenue of $6.06 billion during the quarter, compared to analyst estimates of $5.73 billion. Amgen had a return on equity of 43.18% and a net margin of 10.19%. The firm’s quarterly revenue was up 4.3% on a year-over-year basis. During the same quarter last year, the business posted $3.27 EPS. analysts forecast that Amgen, Inc. will post 13.95 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Friday, September 7th. Investors of record on Friday, August 17th were paid a $1.32 dividend. The ex-dividend date of this dividend was Thursday, August 16th. This represents a $5.28 dividend on an annualized basis and a yield of 2.60%. Amgen’s dividend payout ratio (DPR) is 41.97%.

In related news, EVP Sean E. Harper sold 1,525 shares of the firm’s stock in a transaction on Monday, July 16th. The stock was sold at an average price of $195.71, for a total value of $298,457.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.19% of the company’s stock.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.

Read More: Market Capitalization in the Stock Market

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply